One of The Most Sold Cholesterol Reducing Medications
Lipitor, generically known as atorvastatin, is a statin medication developed to reduce cholesterol. It was approved in 1996 to be used along with diet and exercise to lower the LDL, or bad, cholesterol and triglycerides.
Although there are many anti-cholesterol medications on the market, Lipitor is one of the best selling prescription drugs with sales topping $130 billion by 2012.
FDA Warnings Regarding Lipitor & Type 2 Diabetes
In 2012, the FDA issued a warning that some cholesterol reducing statins could lead to elevated blood sugar levels and the development of Type 2 Diabetes; Lipitor was one of the drugs on the list. Pfizer, the maker of Lipitor, was ordered to add a warning to the drug’s label about this.
In addition, a study conducted by the Women’s Health Initiative concluded, “statin medication use in postmenopausal women is associated with an increased risk for Diabetes Mellitus.”
To date, there has been no recall of Lipitor; however, the FDA continues to warn consumers about the dangers of cholesterol medications.
See the FAQ below for more on research linking Lipitor to Type 2 Diabetes.
Other Health Impacts
The statin class of medications, including Lipitor, has been linked to other serious health issues, including:
- Muscle disease, including Myopathy and Rhabdomyolysis
- Liver complications
- Kidney complications
Added Health Risks for Lipitor Users
Type 2 Diabetes may cause users of the drug to face an increased risk of heart disease, blindness, neuropathy, kidney disease or other complications. As a diabetic, regular blood testing of glucose levels is required along with a more restrictive diet and medicine to control the Diabetes.
Symptoms of Type 2 Diabetes include:
- Increased urination, thirst or hunger
- Unexplained weight loss
- Frequent infections or cuts and bruises that are slow healers
- Numbness in the limbs
Why File a Lipitor Lawsuit?
When you take prescription medication, you rely on your doctor to recommend the best medication for your condition. Your doctor relies on the drug manufacturers to tell the whole story about a drug — the proper use for the drug, potential side effects and more.
Had the link to Type 2 Diabetes been known and the warnings on the labels sooner, controls could have been put in place to monitor such side effects or other medications could have been chosen.
Many have already filed claims against Pfizer alleging that the Diabetes was a direct result of Lipitor treatment and accusing Pfizer of neglecting to provide adequate warnings to consumers of the drug’s full range of health risks.
Receive a Free Evaluation
It’s time to hold pharmaceutical companies accountable for the drugs they produce. The lawyers at Nash & Franciskato Law Firm are ready to help you take legal action to obtain compensation for your pain, suffering, and medical expenses. Contact the Nash & Franciskato Law Firm for a free, no-obligation case evaluation.
Studies Linking Lipitor to Type 2 Diabetes
- February 2010, The Lancet, researchers found that side effects of statins might increase the risk of being diagnosed with Type 2 Diabetes.
- March 2011, Journal of the American College of Cardiology, study that looked specifically at the link between Lipitor and Diabetes found that users of Lipitor had about a 33% higher risk for developing Type 2 Diabetes.
- June 2011, Journal of the American Medical Association, a follow-up study found that among individuals given intensive-dose statin therapy, the rate of diabetes was about one out of every 500 users.
- January 2012, Archives of Internal Medicine, a study found that older women taking Lipitor and other statins might face a 50% increased risk of developing Type 2 Diabetes.
- July 2014, Diabetes Care, a study found that the longer people used statins, the higher their risk of diabetes; those using statin therapy the longest have a 32% increased risk of diabetes over those who do not use a similar drug.
In April of 2013, a petition was filed with the U.S Judicial Panel on Multidistrict Litigation to transfer all pending and future diabetes claims to a single court in the District of South Carolina. While Pfizer opposed this motion, in February 2014 the panel agreed to centralize the cases in South Carolina.